Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aptose Biosciences ( (TSE:APS) ) has shared an announcement.
On March 31, 2026, Aptose Biosciences Inc. shareholders approved a continuance of the corporation from the Canada Business Corporations Act to the Business Corporations Act (Alberta), with more than 92 percent of votes cast in favor. This corporate re-domiciling reflects a governance shift that may streamline regulatory alignment and corporate structure for future operations.
At the same meeting, shareholders also approved a previously announced plan of arrangement under which HS North America Ltd., a wholly owned subsidiary of Hanmi Pharmaceutical Co. Ltd., will acquire all Aptose common shares it does not already own or control, with nearly 85 percent of votes in favor. The strong shareholder support paves the way for Aptose to come under full Hanmi ownership, potentially altering its strategic direction, capital resources, and position within the oncology drug development landscape.
The most recent analyst rating on (TSE:APS) stock is a Hold with a C$2.50 price target. To see the full list of analyst forecasts on Aptose Biosciences stock, see the TSE:APS Stock Forecast page.
Spark’s Take on APS Stock
According to Spark, TipRanks’ AI Analyst, APS is a Neutral.
The score is held back primarily by very weak financial performance (no revenue, ongoing cash burn, negative equity and rising debt). Positive corporate catalysts (promising trial results and a pending acquisition) provide meaningful offset, while technical indicators are mixed-to-weak and valuation metrics are not supportive due to negative earnings and no dividend.
To see Spark’s full report on APS stock, click here.
More about Aptose Biosciences
Aptose Biosciences Inc. is a biotechnology company focused on developing targeted therapies for hematologic malignancies and other cancers. The company operates in the biopharmaceutical sector, pursuing innovative oncology drug candidates for global markets in collaboration with strategic partners such as Hanmi Pharmaceutical.
Average Trading Volume: 4,170
Technical Sentiment Signal: Sell
Current Market Cap: C$5.74M
See more data about APS stock on TipRanks’ Stock Analysis page.